Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201304099 Principal Investigator: Wang-Gillam, Andrea
Title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
Phase: I/II Disease Site: Pancreas
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
There are two parts to this study. The purpose of both parts is to evaluate PEGPH20 at a dose of 3.0 µg/kg in combination with 2 chemotherapy drugs (a standard dose of gemcitabine plus a dose of nab-paclitaxel that has been tested in pancreatic cancer patients) versus gemcitabine and nab-paclitaxel alone (without PEGPH20).
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)